Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 5/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | CCL2 | P13500 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367458 | 0.87 | RIPK1 (0.47) | RIPK1HTR6BRD4CCL2CYP2C19 | |
| SCHEMBL18367457 | 0.87 | RIPK1 (0.47) | RIPK1HTR6BRD4CCL2CYP2C19 | |
| SCHEMBL18367459 | 0.82 | RIPK1 (0.44) | RIPK1HTR6BRD4CCL2CYP2C19 | |
| SCHEMBL18367456 | 0.82 | RIPK1 (0.42) | RIPK1HTR6BRD4CCL2CYP2C19 | |
| SCHEMBL20262416 | 0.81 | RIPK1 (0.53) | RIPK1HTR6CYP2C19KCNH2GRM5 | |
| SCHEMBL20262317 | 0.81 | RIPK1 (0.53) | RIPK1HTR6CYP2C19KCNH2GRM5 | |
| SCHEMBL19659572 | 0.79 | RIPK1 (0.39) | RIPK1HTR6BRD4 | |
| SCHEMBL19659469 | 0.79 | RIPK1 (0.35) | RIPK1GRM5 | |
| SCHEMBL18365813 | 0.78 | RIPK1 (0.40) | RIPK1HTR6CYP3A4GRM5 | |
| SCHEMBL19659443 | 0.77 | GRM5 (0.33) | RIPK1HTR6GRM5CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | RIPK1 3064/4885HTR6 4650/4885BRD4 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.